Search

Displaying results 2011 - 2020 of 4690 in total
  1. Drug

    Rimiducid

    go.drugbank.com/drugs/DB04974
    Investigational

    It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function.

  2. Drug

    Timbetasin

    go.drugbank.com/drugs/DB19119
    Investigational

    Timbetasin is under investigation in clinical trial NCT05555589 (Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2).

  3. Drug

    AZD-1386

    go.drugbank.com/drugs/DB15333
    Investigational

    AZD-1386 is under investigation in clinical trial NCT00945178 (Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of AZD1386 in Healthy Volunteers).

  4. Drug

    Semzuvolimab

    go.drugbank.com/drugs/DB18920
    Investigational

    Semzuvolimab is under investigation in clinical trial NCT03149211 (To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults).

  5. Drug

    Isatuximab

    go.drugbank.com/drugs/DB14811
    ApprovedInvestigational

    [L12099,L12102] It is manufactured by Sanofi-Aventis U.S. under the brand name Sarclisa.[L12102] … [L12099] It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma.

  6. Drug

    Eravacycline

    go.drugbank.com/drugs/DB12329
    ApprovedInvestigational

    It was first approved by the FDA on August 27, 2018 [L4540]. … Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive

  7. Drug

    Fidaxomicin

    go.drugbank.com/drugs/DB08874
    ApprovedInvestigational

    [A190492] Later that year in December, the drug was also approved by the European Medicine Agency.[A190492] In June 2012, fidaxomicin was also granted approval by Health Canada. … [A7445] It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription.

  8. Drug

    Methylphenobarbital

    go.drugbank.com/drugs/DB00849
    Approved

    It has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over phenobarbital.

  9. Drug

    AAV8-RK-RetGC

    go.drugbank.com/drugs/DB32389
    Experimental

    AAV8-RK-RetGC is an adeno-associated virus (AAV) viral vector platform with a serotype 8 capsid with a complementary DNA (cDNA) of the human GUCY2D gene encoding RetGC.

    Synonyms: AAV8-RK-RetGC
  10. Drug

    Hycanthone

    go.drugbank.com/drugs/DB14061
    Experimental

    Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE. Hycanthone was approved by the FDA in 1975 but is no longer used.